Exelixis | EXEL - 营业利润



金融业
股票价格
USD
资产
USD 2.49B
现金及等价物
USD 281.45M
销售成本
USD 20.66M
流动资产
USD 1.25B
流动负债
USD 361.93M
债务
USD 165.93M
EBIT
USD 248.41M
EBITDA
USD 255.4M
员工
1.15K
EPS每股收益
USD 0.91
股本和储备
USD 1.84B
销售毛利
USD 608.03M
债务利息支出
USD 23.4M
利息收入
USD 14.21M
市值
USD 16.3B
净收入
USD 212.05M
营业费用
USD 380.28M
营业利润
USD 248.41M
普通股股本
USD 248.89M
PE价格收益
18.02
税前利润
USD 262.68M
销售收入
USD 628.69M
销售和管理费用
USD 147.63M
股票
USD 28.73M
贸易债权人
USD 39.06M
应收帐款人
USD 322.21M


营业利润 更改 日
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Amgen USD 4.61B 777M 2026-06
AstraZeneca USD 3.16B 3.95B 2026-06
Bayer EUR 827M 2.7B 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Cytokinetics USD -179.17M 2.05M 2026-06
Eisai JPY 24.73B 35.04B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Exelixis USD 248.41M 2.93M 2026-06
Genmab DKK 407M 182M 2026-06
Glaxosmithkline GBP 2.29B 3.08M 2026-03
Incyte USD 700.4M 376.22M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
MacroGenics USD -33.44M 21.34M 2026-03
Merck USD 840M 2.72B 2026-06
Moderna USD -815M 573M 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Novartis USD 4.75B 515M 2026-06
Pfizer USD 667M 4.32B 2026-06
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sanofi EUR 2.27B 771M 2026-03
Takeda JPY 201.42B 215.04B 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Xencor USD -36.6M 41.26M 2026-06